This article highlights few very important aspects :
1)20% of symptomatic individuals will progress to severe or critical disease . 2)Both remdesivir and dexamethasone have now been endorsed globally by multiple COVID-19 treatment guideline committees and have led to improvements in patient outcomes among those requiring hospitalization. 3)Antivirals in trials for early treatment of COVID-19 are MK-4482 (EIDD-2801), an orally bioavailable ribonucleoside inhibitor that was originally developed for influenza (NCT04575597); SNG001, a nebulized formulation of interferon-β1a developed for viral infections in patients with chronic obstructive pulmonary disease (NCT04385095); and camostat mesylate, a serine protease inhibitor approved for treatment of chronic pancreatitis and postoperative reflux esophagitis (NCT04353284). 4)Additionally, monoclonal antibodies are in development by several companies and academic investigators. Early-phase clinical trials sponsored by Eli Lilly (Ly-CoV555) and Regeneron (REGN-COV2) have yielded promising results suggesting that monoclonal antibodies may be effective in decreasing viremia and improving clinical outcomes in patients with early COVID-19. imp: ref: India approves ROCHE/REGENERON for covid 19. 5) Effective, early treatments will also mitigate gaps left by previous and current prevention strategies and curtail forward transmission. It is encouraging that effective outpatient treatments for early COVID-19 are on the horizon; these efforts deserve the full support of the medical community and the public.
Publisher: Dr.Venkat | rangalakshmii netralaya
SRI Gurumangala EyeFoundation Diabetic camp on nov 14